Thus, wild type p53 with low expression of PRR11 and/or SKA2 lung cancer patients represent a functional regulatory axis of p53-PRR11-SKA2, and hence predicts better prognosis than other groups (Figure 5B). The gene discussed is SKA2; the disease is lung carcinoma.